The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma

Kenji Nakamoto1
Masahiko Takeshi2
Toshihiko Hiraoka2,3
Mayuko Eguchi2,4
Yuichiro Nakano1,2
Naomi Otsuka5
Hiroko Hizaki5
Hiromi Akai5
Masayo Hashimoto5

1Department of Ophthalmology, Nippon Medical School, Tokyo, Japan; 2Shinanozaka Clinic, Tokyo, Japan; 3Hiraoka Eye Clinic, Saitama, Japan; 4Musashiurawa Eye Clinic, Saitama, Japan; 5Japan Medical Affairs, Global R&D, Santen Pharmaceutical Co., Ltd., Osaka, Japan

Objective: The aim of this study was to evaluate the 24-hour intraocular pressure (IOP)-control effect of the tafluprost/timolol fixed combination (TAF/TIM-FC) in patients with primary open-angle glaucoma after they switched from the concomitant use of tafluprost and timolol gel-forming solution.

Patients and methods: Twenty patients with primary open-angle glaucoma (12 male and 8 female; mean ± SD age, 57.0±7.1 years) were included in this study. The patients were treated for 8 weeks with the concomitant administration of tafluprost and timolol gel-forming solution (evening dosing). At the end of this period, the patients underwent 24-hour IOP monitoring (measured at 21:00, 01:00, 05:00, 09:00, 13:00 and 17:00). IOP was measured with Goldmann applanation tonometer (GAT) and Icare PRO at sitting position at all timepoints and additionally, at supine position with Icare PRO tonometer at 01:00 and 05:00. The patients were then all switched to TAF/TIM-FC treatment (evening dosing). After 8 weeks, the 24-hour IOP monitoring was repeated.

Results: Nineteen patients completed the study. The mean 24-hour IOPs in the concomitant and TAF/TIM-FC phases were 13.8±2.7 vs 13.3±2.8 mmHg (P=0.0033) with the GAT in the sitting position and 13.96±2.56 vs 13.48±2.56 mmHg (P=0.0120) with the Icare PRO in habitual positions. In comparison with the concomitant phase, significantly lower IOP was observed for the TAF/TIM-FC phase at 21:00 and 01:00 with the GAT and at 01:00 with the Icare PRO. In addition, the maximum IOP and fluctuations in IOP in habitual positions were lower for the TAF/TIM-FC phase than for the concomitant phase.

Conclusion: TAF/TIM-FC showed a stable 24-hour IOP-lowering effect and was equally or more effective than the concomitant use of tafluprost and timolol gel-forming solution.

Keywords: intraocular pressure, tafluprost, circadian IOP, 24-hour IOP, timolol gel

Introduction

Glaucoma is a progressive disease characterized by changes to the optic nerve head and visual field defects; its fundamental pathology for functional structural abnormality is glaucomatous optic neuropathy. Currently, the only reliable treatment is intraocular pressure (IOP) reduction therapy, based on the evidence that it slows the progression of visual field defects.1
Over the years, 24-hour IOP control has been the focus of attention. Indeed, there are many studies investigating the 24-hour efficacy of various ocular hypotensive medicines. Beta adrenergic blockers including timolol were reported to show significant mean 24-hour IOP reduction and reduced efficacy at night time. On the other hand, prostaglandin analogs, which are popular first-line treatment for glaucoma, were found to have potent 24-hour IOP reduction efficacy throughout the day including night time. Tafluprost, one of the prostaglandin analogs, exhibited significantly lower peak IOP, narrower fluctuation and more efficiency at night compared with latanoprost with primary open angle glaucoma (POAG) in a 24-hour monitoring study using preservative-free formulation.

Generally, a single-agent therapy cannot achieve sufficient reduction of the IOP in some patients, requiring two or more agents to be used in the treatment. When multiple drugs are used concomitantly, the main problem is poor adherence to the medication. To improve adherence, a fixed-combination drug is used for patients who need multiple IOP-lowering medications. Tafluprost 0.0015%/timolol 0.5% fixed-combination solution (TAF/TIM-FC), a once-a-day instillation, has been shown to demonstrate three-point diurnal IOP reduction efficacy noninferior to the concomitant use of tafluprost 0.0015% ophthamlic solution once a day and timolol maleate ophthamlic 0.5% solution twice a day in the Phase III study conducted in Japan and Europe. However, to date, there has been no evaluation of TAF/TIM-FC’s 24-hour IOP-lowering profile and its efficacy has not been compared with that of the concomitant use of the medications.

In this study, we evaluated the 24-hour IOP control efficacy of TAF/TIM-FC, both in sitting and habitual positions (ie, sitting during the day and supine at night), in patients with POAG, after switching from the concomitant use of tafluprost and timolol gel-forming ophthalmic solution 0.5%.

Patients and methods
This study was approved by the Ethics Committee of the Medical Corporation Shinanokai Shinanozaka Clinic, and was conducted from August 2016 to January 2017 at Shinanokai Clinic (Tokyo, Japan) in accordance with the tenets of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. All patients were fully informed of the purpose and procedures of this study, and all provided written informed consent to the investigators. This study was registered with the University Hospital Medical Information Network clinical trials registry (ID: UMIN000023883).

Patients
Eligible patients for the study were those ≥20 years of age with unilateral or bilateral POAG and who were expected to visit the clinic according to the observation schedule determined in the study protocol. The exclusion criteria were as follows: 1) any corneal abnormalities or other diseases that could interfere with accurate IOP measurement with a Goldmann applanation tonometer (GAT); 2) a history of corneal refractive surgery; 3) corrected visual acuity of 0.6 or less; 4) advanced visual field defects; 5) active extraocular disease, or ocular or eyelid inflammatory or infectious diseases; 6) a history of anterior or intraocular surgery; 7) a history of glaucoma surgery, including laser treatment; 8) allergy to the ingredients used in this study; 9) pregnancy, lactation, possibly pregnancy, a wish to become pregnant during the study period or unable to conduct appropriate contraception during the study; 10) scheduled medications or therapies prohibited during the study period; 11) contraindications to beta blockers, such as bronchial asthma or poorly controlled cardiac failure and 12) anyone the principal or other investigators considered ineligible for enrollment.

During the study period, the patients were prohibited from using any anti-glaucoma eye drops other than the study drugs, or any oral or intravenous IOP-lowering agents and corticosteroid drugs. Ocular laser surgery and invasive surgery were also prohibited. In addition, contact lens wearing was prohibited during the hospital visits (at weeks 8 and 16). Although the patients were allowed to use drugs and therapies other than those that were prohibited, they did not commence, discontinue or change the dosage of any drugs that could affect IOP, such as antihypertensive drugs or therapies, during the study period.

Procedures
This study was designed as a prospective, single-arm, open-label trial. An outline of the study is presented in Figure 1. During the study period, each patient routinely underwent a comprehensive clinical examination that included measuring IOP with a GAT, slit-lamp biomicroscopy, fundoscopy, blood pressure determination, and heart rate measurement. In addition, gonioscopy was conducted at the time of enrollment, and the central corneal thickness was measured 4 weeks later. Visual acuity tests were conducted at the time of enrollment and the end of the study. Prior to the patient’s submission of the informed consent, visual field tests results had been recorded for up to 6 months.

For the first 8 weeks of the study, all patients concomitantly instilled benzalkonium chloride containing tafluprost...
Twenty-four-hour IOP control by tafluprost/timolol fixed combination

0.0015% (Tapros®; Santen Pharmaceutical Co., Ltd., Osaka, Japan) and timolol gel-forming solution 0.5% (Timoptol XE 0.5%®; Santen Pharmaceutical Co., Ltd.) once each evening (the "concomitant phase"). The timolol gel-forming solution was instilled at least 10 minutes after the instillation of tafluprost. At the end of the concomitant phase, patients were admitted to hospital and underwent a 24-hour IOP measurement process. During this, IOP was measured in the sitting position with the Icare® PRO tonometer (Icare Finland Oy, Espoo, Finland) and then with the GAT; a total of six measurements were made at 4-hour intervals (at 21:00, 01:00, 05:00, 09:00, 13:00 and 17:00). In addition, IOP was measured in the supine position with the Icare PRO at 01:00 and 05:00 after the measurements in the sitting position. The maximum acceptable variation in the time of the IOP measurement was ±30 minutes. Blood pressure and heart rate were also measured at the same time as the IOP measurement. For the following 8 weeks, the patients used benzalkonium chloride containing tafluprost 0.0015%/timolol 0.5% fixed-combination solution (Tapcom®, Santen Pharmaceutical Co., Ltd.), instilling one dose each evening (the "TAF/TIM-FC phase"). At the end of this period, the 24-hour IOP measurement protocol was repeated in the hospital. For patients with bilateral POAG with both eyes meeting the eligibility criteria, the eye with the higher mean 24-hour IOP at week 8 was selected as the study eye; if the IOP was equal in both eyes, the right eye was selected for the study.

At each time point, IOP was measured three times with the GAT and the median value adopted for the analysis. With the Icare PRO, the measurement was made at least six times until "deviation OK" was displayed on the tonometer’s screen, and the mean of these values was adopted. On the day before hospitalization for the 24-hour IOP measurement, the patients were asked to instill the eye drops between 20:00 and 22:00. On the days of hospitalization, the eye drops were administered at 21:00 after the measurements of IOP, blood pressure and heart rate. The same observer made the 24-hour IOP measurements for both the concomitant phase and the TAF/TIM-FC phase.

Adherence to the instillation schedule was recorded at each visit and classified as follows: “complete instillation (100% instillation)”, “sometimes forgot instillation (75%–99% instillation)”, “instilled half of the times as scheduled (25%–74% instillation)” and “instilled a few times as scheduled (<25% instillation).” At week 12, a questionnaire was given to the patients asking for their impression of TAF/TIM-FC in comparison with the concomitant use of medications. They were asked about the frequency of forgetting instillation (increased, decreased or unchanged), its user-friendliness (more user-friendly, less user-friendly or unchanged) and their preference of continuation (prefer the fixed combination, prefer the concomitant use or no preference).

Statistical analysis

Data regarding the backgrounds, questionnaire and profiles of adverse events of all the enrolled patients, and the other data for all the patients who completed the study, were analyzed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). Summary statistics (mean and SD) of the following were calculated for each 24-hour measurement: 24-hour IOP, diurnal IOP (09:00, 13:00, 17:00 hours), nocturnal IOP (21:00, 01:00, 05:00), maximum, minimum and fluctuation (maximum − minimum). A mixed-effect model was used for the analysis of 24-hour, diurnal and nocturnal IOPs and the individual time points, calculating $P$-values by using least squares estimation and the 95% CI. The changes in the maximum value, the minimum value and the fluctuation during 24 hours in the treatment period between
the TAF/TIM-FC phase and the concomitant phase were compared using the paired *t*-test. Sign tests were used for the analysis of the questionnaire responses. *P*-values <0.05 were considered significant.

**Results**

**Patients**

Initially, 21 patients were enrolled, but deviation from the study criteria was found in 1 patient after the submission of informed consent. The study, therefore, started with 20 patients who complied with the inclusion and exclusion criteria. One patient withdrew during the study period for personal reasons; the remaining 19 patients completed the study. The characteristics of the patients are presented in Table 1.

Across the whole study period, 89.5%–100% of the patients reported “perfect adherence to the scheduled instillation (100% instillation)” and none reported “low adherence to the scheduled instillation (25%–74% instillation)” or “poor adherence to the scheduled instillation (<25% instillation)”.

**Twenty-four-hour IOP measurement**

Table 2 presents mean values for the patients’ 24-hour IOP profiles measured with the GAT in the sitting position. The mean 24-hour IOP and nocturnal IOP were significantly lower for the TAF/TIM-FC phase than for the concomitant phase at two time points, 01:00 (14.62±2.88 vs 12.57±2.42 mmHg, *P*=0.0001) and 05:00 (14.42±2.18 vs 13.25±2.13 mmHg, *P*=0.0126). The 24-hour IOP profile in the habitual positions (sitting during the day and supine at night) measured with the Icare PRO is given in Table 3. Similar to the measurements made in the sitting position, the mean 24-hour IOP and nocturnal IOP were significantly lower in the TAF/TIM-FC phase than in the concomitant phase (24-hour IOP: 13.96±2.56 vs 13.48±2.56 mmHg, *P*=0.0120; nocturnal IOP: 14.74±2.53 vs 13.81±2.68 mmHg, *P*=0.0006). With the concomitant therapy, IOP increased slightly during the nocturnal period, whereas with the TAF/TIM-FC therapy, it remained nearly constant throughout the 24-hour period (Figure 3). At 01:00, the mean IOP was significantly lower in the TAF/TIM-FC phase than in the concomitant phase (16.33±2.56 vs 14.53±2.83 mmHg, *P*=0.0001). In addition, the maximum IOP and fluctuation were lower in the TAF/TIM-FC phase than in the concomitant phase (*P*=0.0011 and 0.0097, respectively).

**Table 1 Patients’ characteristics**

<table>
<thead>
<tr>
<th>N=20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Sex (male/female)</td>
</tr>
<tr>
<td>Corrected visual acuity</td>
</tr>
<tr>
<td>Mean defect (dB)</td>
</tr>
<tr>
<td>Spherical equivalent (D)</td>
</tr>
<tr>
<td>CCT (µm)</td>
</tr>
</tbody>
</table>

**Notes:** Data are presented as mean ± SD (N=20). Corrected visual acuity is presented in LogMAR. The mean defect was measured with Octopus (Ver. 301, Haag-streit, Koeniz, Switzerland).

**Abbreviation:** CCT, central cornea thickness.

**Table 2 Twenty-four-hour IOP profiles for the concomitant and TAF/TIM-FC treatments measured using a Goldmann Applanation Tonometer**

<table>
<thead>
<tr>
<th></th>
<th>Concomitant Mean ± SD</th>
<th>TAF/TIM-FC Mean ± SD</th>
<th><em>P</em>-valuea</th>
</tr>
</thead>
<tbody>
<tr>
<td>21:00</td>
<td>14.5±3.3</td>
<td>13.0±2.2</td>
<td>0.0009</td>
</tr>
<tr>
<td>01:00</td>
<td>13.8±3.0</td>
<td>12.8±2.6</td>
<td>0.0168</td>
</tr>
<tr>
<td>05:00</td>
<td>13.7±2.7</td>
<td>12.9±2.4</td>
<td>0.0720</td>
</tr>
<tr>
<td>09:00</td>
<td>14.2±2.3</td>
<td>13.6±3.0</td>
<td>0.1863</td>
</tr>
<tr>
<td>13:00</td>
<td>13.3±2.6</td>
<td>13.3±2.8</td>
<td>0.9042</td>
</tr>
<tr>
<td>17:00</td>
<td>13.3±2.5</td>
<td>13.9±3.0</td>
<td>0.1186</td>
</tr>
<tr>
<td>Mean 24-hour</td>
<td>13.8±2.7</td>
<td>13.3±2.8</td>
<td>0.0033</td>
</tr>
<tr>
<td>Diurnal</td>
<td>13.6±2.4</td>
<td>13.6±2.9</td>
<td>0.9448</td>
</tr>
<tr>
<td>Nocturnal</td>
<td>14.0±3.0</td>
<td>12.9±2.7</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

**Notes:** The IOPs were measured in the sitting position (n=19). Diurnal: mean of the IOPs at 09:00, 13:00 and 17:00. Nocturnal: mean of the IOPs at 21:00, 01:00 and 05:00. *Fixed-effect model P*-value comparing the concomitant and TAF/TIM-FC treatments. Paired *t*-test *P*-value for the mean difference in the two treatments.

**Abbreviations:** IOP, intraocular pressure; TAF/TIM-FC, tafluprost/timolol fixed combination.
Blood pressure and heart rate

There were no significant differences in 24-hour systolic blood pressure, diastolic blood pressure or heart rate between the two phases, either over the whole 24-hour period or at any time point (Table 4). Indeed, no remarkable changes in values were observed throughout the day (data not shown).

Questionnaire results

In their responses to the questionnaire on the use of the eye drops, 6 of the 20 patients (30.0%) answered that their frequency of instillation forgetfulness decreased after switching to TAF/TIM-FC ($P=0.0313$ vs the number of those who answered “increased”); the remaining 14 patients (70.0%) reported no change after switching, with none reporting increased forgetfulness (Figure 4). Nine of the patients felt the treatment after switching to be more user-friendly ($P=0.0215$ vs the number of those who answered “less user-friendly”), whereas 10 (50.0%) reported no difference in user-friendliness between the two treatments. All preferred to continue with the fixed-combination drug than return to the concomitant treatment ($P<0.0001$ vs the number of those who chose “concomitant use”).

Safety

Table 5 summarizes the adverse events experienced by the patients related with the two study treatments. Both treatments were well tolerated. No serious adverse events occurred during the study period.

Discussion

The aim of this study was to investigate the 24-hour IOP-lowering efficacy of TAF/TIM-FC, in both the sitting and habitual positions, after switching from the concomitant use of tafluprost and timolol gel. To the best of our knowledge, this is the first study to evaluate the 24-hour efficacy of
TAF/TIM-FC and compare this with the concomitant use. When measured in the sitting position with the GAT, IOP was stable at a low level in both the concomitant phase and the TAF/TIM-FC phase throughout the 24-hour testing period. In addition, TAF/TIM-FC demonstrated small but statistically significant reduction of the 24-hour and nocturnal IOP after switching from the concomitant use (0.5 and 1.1 mmHg, respectively). Because the Early Manifest Glaucoma Trial has shown that a difference of 1 mmHg in IOP can offer a 10% protection against the progression of glaucoma, we consider that the reductions shown in this study might also be clinically significant.\(^12\)

Previous studies have compared fixed combinations of prostaglandin analogs and timolol with the concomitant use of the ingredients,\(^13–17\) with most of them reporting lower efficacy for the fixed-combination drugs.\(^18\) These results were mostly explained as resulting from the declining number of instillations of timolol in fixed-combination drugs than when the drugs were used concomitantly. Timolol gel 0.5% was provided as a once-daily dosing formulation, and it showed the same efficacy as 0.5% timolol solution for POAG or ocular hypertension because of the extended precorneal residence time.\(^19–21\) Indeed, in a randomized parallel-group study of 90 POAG patients conducted by Özyol and Özyol, the mean diurnal IOP with the concomitant use of evening-dosed latanoprost and morning-dosed timolol gel was significantly lower than that with evening-dosed latanoprost/timolol maleate fixed combination after 8 weeks of treatment.\(^22\)

It is unclear why there were statistically significant differences between the two treatments in this study. TAF/TIM-FC was designed for improving timolol penetration into the eye to compensate for the possible diminished effect of timolol arising from the decreased instillation frequency from twice daily with the concomitant use to once daily. Indeed, timolol penetration into the eye with TAF/TIM-FC has been reported to be higher than that with the timolol mono-preparation.\(^23,24\) The reason for the lowered IOP with TAF/TIM-FC in this study may be partly because of the good penetration of timolol into the anterior chamber.

In this study, IOP was measured with the Icare PRO tonometer in addition to the GAT. The Icare is a user-friendly, handheld rebound tonometer with a disposable probe that prevents infection during the measurement. Icare PRO allows IOP to be measured in the supine position as well as in the normal upright position. It has been reported to show good reproducibility of measurements made with the GAT in the sitting position.\(^25\) This study also demonstrated that the mean
Twenty-four-hour IOP control by tafluprost/timolol fixed combination

24-hour IOP and IOP at individual time points measured with the Icare PRO in the sitting position were similar to those measured with the GAT (data not shown). In this study, IOP was also measured with Icare PRO in the habitual positions (sitting during the day and supine at night). The mean value of 24-hour IOP was in rough agreement with that measured by the GAT in the sitting position for both treatment phases. Furthermore, maximum IOP and the fluctuation in IOP when measured in the habitual positions were statistically lower in the TAF/TIM-FC phase than in the concomitant phase. This result suggests that TAF/TIM-FC treatment could result in lower IOP for POAG patients even at night in the supine position; thus, TAF/TIM-FC may be an appropriate treatment for careful 24-hour IOP control in daily life.

The results of the questionnaire on switching to the TAF/TIM-FC treatment revealed that almost all the patients experienced either no change or improved in their frequency of instillation and user-friendliness after switching treatments, and all patients preferred to continue using TAF/TIM-FC. This suggests that a fixed-combination therapy can improve patient adherence because of the reduced number of daily instillations. The clinical practice guidelines for glaucoma treatment in Japan note that poor compliance is one of the most important factors for the progression of glaucomatous optic neuropathy.1 The optimal control of IOP requires topical therapy for glaucoma treatment to continue over a long time. The selection of user-friendly eye drops could be useful for the long-term control of IOP.

This study had some limitations: First, there was no washout period between the two treatment periods. However, the patients had been treated for 8 weeks before the 24-hour hospital stay for IOP measurements, so the impact of the prior treatment is considered minimal. Second, this trial evaluated switching from one treatment to the other, so an order effect bias was inevitable. The questionnaire focused only on how patients felt after switching, and the results may have contained some bias because of the order effect. In addition, baseline 24-hour IOP measurements were not made, so the reduction in IOP from the previous untreated period could not be established. Other limitations include this being a single-center trial, the small study population and the short-term follow-up.

Conclusion

This study examined the effects of TAF/TIM-FC over 24 hours after switching from the concomitant use of tafluprost and timolol gel-forming solution in POAG patients, and demonstrated TAF/TIM-FC maintained 24-hour IOP equal to or lower than that of the concomitant use, in both the sitting and habitual positions. This showed that TAF/TIM-FC instilled at one drop a day could be beneficial for patients, allowing their IOP to be maintained at a level as low as with the concomitant use.

Acknowledgments

This study was funded by Santen Pharmaceutical Co., Ltd. (Osaka, Japan). The funding organization participated in the design of the study, interpretation of the data, review and approval of the manuscript, and had no role in the data
collection and analysis of data derived from this study. Data management and statistical analysis were conducted by Biostatistical Research Corporation (Tokyo, Japan). Etsuyo Miyamoto and Izumi Furutani are employees of Santen Pharmaceutical Co., Ltd. Etsuyo Miyamoto contributed toward drafting and revising the protocol and reviewing the paper. Izumi Furutani contributed toward reviewing the paper.

Disclosure
Kenji Nakamoto received consultant fee from Santen Pharmaceutical Co., Ltd. Naomi Otsuka, Hiroko Hizaki, Hiromi Akai and Masayo Hashimoto are employees of Santen Pharmaceutical Co., Ltd. The other authors report no conflicts of interest in this work.

References
10. Kuwazac Y. DE-111 collaborative trial group. [Phase III double-masked study of fixed combination tafluprost 0.0015%/timolol 0.5% (DE-111) versus tafluprost 0.0015%/ alone or given concomitantly with timolol 0.5% in primary open angle glaucoma and ocular hypertension]. J Eye (Atarashii Ganka). 2013;30(8):1185–1194. Japanese.
16. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with openangle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392–399.
Twenty four-hour IOP control by tafluprost/timolol fixed combination